금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Stock Market Today, Oct. 14: Bank of America Shares Fall 5% on Earnings Miss and Compliance Penalty
Adjusted EPS of $1.08 fell short of estimates, while a $1.2 billion anti-money-laundering penalty we...
GBP/JPY Price Forecast: Failed breakout puts 208.00 in focus
The GBP/JPY dives over 0.45% on Wednesday as market mood turns sour on red-hot US inflation data, wh...
Inside Google’s $200bn Wall Street finance machine for Anthropic
Private credit, chip leases and data centre guarantees underpin a vast new model for AI spending
The UAE’s imperial push into Africa
The Gulf state is investing heavily in land, ports and influence across the continent. But its entangled goals come at a price
Can Democrats seize Congress from Trump?
The races, the money and the issues that will determine the final half of Trump’s second term
Do natural GLP-1s work?
Alternatives to weight-loss drugs are gaining traction. But do they make a difference?
Russia expands shadow LNG fleet ahead of EU ban
Growing number of ships will help Moscow continue exporting liquefied natural gas when sanctions tighten next year
Bessent’s yen intervention signals new era of US ‘currency activism’
Bid to support Japan’s currency shows US is ready to scupper trades that push against its interests
US states accuse Trump administration of ‘sham’ tariff probe
More than 20 attorneys-general launch legal challenge to duties for alleged forced labour violations
Palantir forecasts greater demand from US groups for its AI software
Tech company posts second-quarter results with US sales climbing 23%
Israel’s defence minister triggers row after sacking general on TV
Opposition decries attempt by Israel Katz to oust commander responsible for West Bank as sop to far-right voters
How big was the American JPY intervention?
We can but guess, for now
AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough
Sheer mass helps when enlarged balance sheets allow for bigger bets on potential blockbuster drugs
AstraZeneca investors raise concerns over mega-merger talks
Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb